Technology-Conditioned APMs: Paying for Demonstrated Value, Not Just Adoption

Telemedicine is often cost-effective (ICER ~$4,500/QALY; Shah, 2024), but AI and advanced imaging show context-dependent value with risk of technology creep. Building on outcomes-based payment logic in pharmaceuticals (Hlávka et al., 2021), this project designs APM riders that adjust payments based on realized incremental value (e.g., risk-adjusted outcomes, avoidable utilization) attributable to specific technologies at the provider level. We’d embed stepped-wedge rollouts, regression discontinuities (threshold-based access), and instrumental variables (e.g., bandwidth shocks) to generate credible causal estimates, then feed those into a Bayesian hierarchical engine that updates provider-specific value scores quarterly. Payments increase when tech demonstrably improves value; they taper or reverse when it doesn’t. Critically, given evidence that EHR nudges alone often fail due to workflow misfit and clinician disagreement (Viswanadham et al., 2025), the model explicitly includes workflow integration and clinician acceptance metrics as prerequisites for positive payment adjustments. Novelty: most payment models reward adoption or process, not measured technology-induced value. Impact: a self-correcting mechanism that encourages diffusion where tech helps and discourages wasteful uptake where it doesn’t.

References:

1. The economics of alternative payment models for pharmaceuticals. J. Hlávka, Jeffrey C. Yu, D. Goldman, D. Lakdawalla (2021). European Journal of Health Economics.
2. The Intersection of Technology and Health Economics: Innovations and Challenges. Syed Shah (2024). Premier Journal of Public Health.
3. When Nudges Don’t Budge: A Mixed Methods Study of Why EHR-Based Deprescribing Nudges Failed to Change Provider Behavior. Ratnalekha V N Viswanadham, H. Belli, T. R. Martinez, Christina Wong, Saul Blecker, Andrea B Troxel, Devin M. Mann (2025). Research Square.